D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
PTGX holding history
Protagonist Therapeutics, Inc in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
PTGX overviewAll 13F holders of PTGXFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 13
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −47,361−100.0% | Sold out | Holders |
| Q1 2025 | 47,361 | $2.29M | <0.1% | +41,657+730.3% | Added | Holders |
| Q4 2024 | 5,704 | $220.2K | <0.1% | −21,121−78.7% | Reduced | Holders |
| Q3 2024 | 26,825 | $1.21M | <0.1% | +13,673+104.0% | Added | Holders |
| Q2 2024 | 13,152 | $455.7K | <0.1% | −22,488−63.1% | Reduced | Holders |
| Q1 2024 | 35,640 | $1.03M | <0.1% | +35,640 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −72,686−100.0% | Sold out | Holders |
| Q2 2023 | 72,686 | $2.01M | <0.1% | −126,830−63.6% | Reduced | Holders |
| Q1 2023 | 199,516 | $4.59M | <0.1% | +11,480+6.1% | Added | Holders |
| Q4 2022 | 188,036 | $2.05M | <0.1% | +44,961+31.4% | Added | Holders |
| Q3 2022 | 143,075 | $1.21M | <0.1% | +143,075 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −43,286−100.0% | Sold out | Holders |
| Q4 2021 | 43,286 | $1.48M | <0.1% | −72,627−62.7% | Reduced | Holders |
| Q3 2021 | 115,913 | $2.05M | <0.1% | −132,322−53.3% | Reduced | Holders |
| Q2 2021 | 248,235 | $11.1M | <0.1% | +47,255+23.5% | Added | Holders |
| Q1 2021 | 200,980 | $5.21M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.